The CYP2R1 antibody is a crucial tool for studying the CYP2R1 enzyme, a member of the cytochrome P450 superfamily primarily expressed in the liver. CYP2R1 plays a pivotal role in vitamin D metabolism by catalyzing the hydroxylation of vitamin D3 (cholecalciferol) to 25-hydroxyvitamin D3 [25(OH)D3], the major circulating form of vitamin D and a key biomarker of vitamin D status. This enzyme’s activity is essential for maintaining calcium homeostasis, bone health, and immune function. Mutations in the CYP2R1 gene are linked to hereditary vitamin D deficiency disorders, underscoring its physiological significance.
CYP2R1 antibodies are widely used in research to detect and quantify CYP2R1 protein expression in tissues, particularly in hepatic and extrahepatic studies. They enable investigations into CYP2R1 regulation under various pathological conditions, such as chronic liver disease, autoimmune disorders, and malignancies, where vitamin D dysregulation is implicated. These antibodies are also employed to explore CYP2R1’s interactions with other metabolic pathways and its response to pharmacological agents or environmental factors.
Available as monoclonal or polyclonal variants, CYP2R1 antibodies are validated for techniques like Western blotting, immunohistochemistry, and ELISA. Their specificity and sensitivity make them vital for advancing understanding of vitamin D biology, genetic disorders, and therapeutic strategies targeting CYP2R1 activity.